Clinical Study

A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (Anti?Pd L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy In Pd L1?Selected Patients With Completely Resected S

Posted Date: May 14, 2017

  • Investigator: Nagla Abdel Karim
  • Co-Investigator: Lauren Hendricks
  • Specialties: Hematology/Oncology, Oncology, Cancer, Lung Cancer, Surgical Oncology
  • Type of Study: Drug

The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and your NSCLC. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of NSCLC. Atezolizumab is a


To Be Eligible, Patients Must Have Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer


Go29527, Cancer, Resected Nsclc, Lung, Null

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    UC Study Finds Organs from HCV Donors May Be Safe for Liver Transplant

    A UC researcher says livers from HCV patients who test positive for theantibody made to fight the disease may pose a modest risk of infection and beacceptable for transplant